These are biotech's 44 most promis­ing star­tups of the last half-decade — here's how they've end­ed up

When an­nu­al­ly pro­claim­ing which star­tups are poised to be­come the next big thing in biotech, you ought to track their progress every so of­ten.

In the past five years, End­points News has pro­filed 44 pri­vate biotech star­tups ex­hibit­ing the hall­marks of great po­ten­tial — sci­en­tif­ic rig­or, lead­er­ship gus­to, deep pock­ets, am­bi­tion to take on what oth­ers haven’t or a fresh take on the in­dus­try.

So, in ad­vance of an­nounc­ing an­oth­er batch of hon­orees this week, it’s time to re­flect on the sta­tus of pre­vi­ous End­points 11 win­ners. (And sor­ry, Class of 2019, for ne­glect­ing to se­lect any com­pa­nies from your year.)

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER